Vascular Endothelial Growth Factor Receptor Inhibitor SU5416 Suppresses Lymphocyte Generation and Immune Responses in Mice by Increasing Plasma Corticosterone

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Grailer, Jamison J ^a   Steeber, Douglas A ^a  

^a UNIVERSITY OF WISCONSIN MILWAUKEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BEVACIZUMAB; CORTICOSTERONE; GLUCOCORTICOID RECEPTOR; SEMAXANIB; TRANSFORMING GROWTH FACTOR BETA; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ADRENALECTOMY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CORTICOSTEROID RELEASE; CORTICOSTERONE BLOOD LEVEL; HOMEOSTASIS; IMMUNE DEFICIENCY; IMMUNIZATION; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MOUSE; NONHUMAN; THYMOCYTE; THYMUS ATROPHY; WEIGHT GAIN; ACTIVE IMMUNIZATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CYTOLOGY; DRUG EFFECTS; LYMPHOCYTE; METABOLISM;

ANIMALS; CORTICOSTERONE; IMMUNITY, ACTIVE; INDOLES; LYMPHOCYTES; MICE; MICE, INBRED C57BL; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; ENDOTHELIAL CELLS; GLYCOPROTEINS; LIVER; LUNG; LYMPHATIC VESSELS; NEOVASCULARIZATION, PHYSIOLOGIC; TISSUE SURVIVAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; YOLK SAC;

EID: 84884195188     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075390     Document Type: Article

References (52)

1. Lemmon MA, Schlessinger J, (2010) Cell signaling by receptor tyrosine kinases. Cell 141: 1117-1134.
2. Fong TA, Shawver LK, Sun L, Tang C, App H, et al. (1999) SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106.
3. Itokawa T, Nokihara H, Nishioka Y, Sone S, Iwamoto Y, et al. (2002) Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling. Mol Cancer Ther 1: 295-302.
4. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, et al. (2001) The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 97: 1413-1421.
5. Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, et al. (2002) SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 100: 2941-2949.
6. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, et al. (2000) The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6: 4848-4858.
7. Vajkoczy P, Menger M, Vollmer B, Schilling L, Schmiedek P, et al. (1999) Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1: 31-41.
8. Heymach JV, Desai J, Manola J, Davis DW, McConkey DJ, et al. (2004) Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 10: 5732-5740.
9. Stadler WM, Cao D, Vogelzang NJ, Ryan CW, Hoving K, et al. (2004) A randomized phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 10: 3365-3370.
10. Zangari M, Anaissie E, Stopeck A, Morimoto A, Tan N, et al. (2004) Phase II study of SU516, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clin Cancer Res 10: 88-95.
11. Author not listed, (2002) Pharmacia's SU5416 not effective (letter). Expert Rev Anticancer Ther 2: 5.
12. Haroon ZA, Amin K, Saito W, Wilson W, Greenberg CS, et al. (2002) SU5416 delays wound healing through inhibition of TGF-β1 activation. Cancer Biol Ther 1: 121-126.
13. Feige JJ, Cochet C, Savona C, Shi DL, Keramidas M, et al. (1991) Transforming growth factor beta 1: an autocrine regulator of adrenocortical steroidogenesis. Endocr Res 17: 267-279.
14. Benjamim CF, Hogaboam CM, Kunkel SL, (2004) The chronic consequences of severe sepsis. J Leukoc Biol 75: 408-412.
15. Lara Jr PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, et al. (2003) SU5416 plus interferon alpha in advanced renal cell carcinoma: A phase II california cancer consortium study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res 9: 4772-4781.
16. Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, et al. (2007) Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res 13: 5862-5868.
17. Peterson AC, Swiger S, Stadler WM, Medved M, Karczmar G, et al. (2004) Phase II study of the FLK-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin Cancer Res 10: 4048-4054.
18. Woodrum C, Nobil A, Dabora SL, (2010) Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med 8: 1-18.
19. Chernoguz A, Crawford K, Vandersall A, Rao M, Willson T, et al. (2012) Pretreatment with anti-VEGF therapy may exacerbate inflammation in experimental acute colitis. J Pediatr Surg 47: 347-354.
20. Bock F, Onderka J, Dietrich T, Bachmann B, Kruse FE, et al. (2007) Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 48: 2545-2552.
21. Steeber DA, Green NE, Sato S, Tedder TF, (1996) Lymphocyte migration in L-selectin-deficient mice: altered subset migration and aging of the immune system. J Immunol 157: 1096-1106.
22. Kodera M, Grailer JJ, Karalewitz AP, Subramanian H, Steeber DA, (2008) T lymphocyte migration to lymph nodes is maintained during homeostatic proliferation. Microsc Microanal 14: 211-224.
23. Engel P, Zhou LJ, Ord DC, Sato S, Koller B, et al. (1995) Abnormal B lymphocyte development, activation and differentiation in mice that lack or overexpress the CD19 signal transduction molecule. Immunity 3: 39-50.
24. Shrestha B, Hashiguchi T, Ito T, Miura N, Takenouchi K, et al. (2010) B cell-derived vascular endothelial growth factor A promotes lymphangiogenesis and high endothelial venule expansion in lymph nodes. J Immunol 184: 4819-4826.
25. Arbones ML, Ord DC, Ley K, Radich H, Maynard-Curry C, et al. (1994) Lymphocyte homing and leukocyte rolling and migration are impaired in L-selectin-deficient mice. Immunity 1: 247-260.
26. Steeber DA, Green NE, Sato S, Tedder TF, (1996) Humoral immune responses in L-selectin-deficient mice. J Immunol 157: 4899-4907.
27. Screpanti I, Morrone S, Meco D, Santoni A, Gulino A, et al. (1989) Steroid sensitivity of thymocyte subpopulations during intrathymic differentiation. J Immunol 142: 3378-3383.
28. Gardiner PF, Montanaro G, Simpson DR, Edgerton VR, (1980) Effects of glucocorticoid treatment and food restriction on rat hind limb muscles. Am J Physiol 238: E124-130.
29. Stojic-Vukanic Z, Rauski A, Kosec D, Radojevic K, Pilipovic I, et al. (2009) Dysregulation of T-cell development in adrenal glucocorticoid-deprived rats. Exp Biol Med 9: 1067-1074.
30. Mao J, Regelson W, Kalimi M, (1992) Molecular mechanism of RU 486 action: a review. Mol Cell Biochem 109: 1-8.
31. Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, et al. (2002) SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 62: 65-74.
32. Laakko T, Fraker P, (2002) Rapid changes in the lymphopoietic and granulopoietic compartments of the marrow caused by stress levels of corticosterone. Immunology 105: 111-119.
33. Steer JH, Ma DT, Dusci L, Garas G, Pedersen KE, et al. (1998) Altered leucocyte trafficking and suppressed tumour necrosis factor alpha release from peripheral blood monocytes after intra-articular glucocorticoid treatment. Ann Rheum Dis 57: 732-737.
34. Yao Z, DuBois DC, Almon RR, Jusko WJ, (2008) Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats. J Pharm Sci 97: 2820-2832.
35. Caldwell CW, Lacombe F (2000) Evaluation of peripheral blood lymphocytosis. Santa Cruz: Academic Information Systems, Inc. 125 p.
36. Sprent J, (1973) Circulating T and B lymphocytes of the mouse. I. Migratory properties. Cell Immunol 7: 10-39.
37. Islam Z, King LE, Fraker PJ, Pestka JJ, (2003) Differentiall induction of glucocorticoid-dependent apoptosis in murine lymphoid subpopulations in vivo following coexposure to lipopolysaccharide and vomitoxin (deoxynivalenol). Toxicol Appl Pharmacol 187: 69-79.
38. Lowenberg M, Verhaar AP, Bilderbeek J, van Marle J, Buttgereit F, et al. (2006) Glucocorticoids cause rapid dissociation of a T-cell-receptor-associated protein complex containing LCK and FYN. EMBO Rep 7: 1023-1029.
39. Lanza L, Scudeletti M, Puppo F, Bosco O, Peirano L, et al. (1996) Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol 103: 482-490.
40. Bowen DL, Fauci AS, (1984) Selective suppression effects of glucocorticoids on the early events in the human B cell activation process. J Immunol 133: 1885-1890.
41. Kim YS, Hong SW, Choi JP, Shin TS, Moon HG, et al. (2009) Vascular endothelial growth factor is a key mediator in the development of T cell priming and its polarization to type I and type 17 T helper cells in the airways. J Immunol 183: 5113-5120.
42. Basu A, Hoerning A, Datta D, Edelbauer M, Stack MP, et al. (2010) Vascular endothelial growth factor-mediated signaling in human CD45RO+ CD4+ T cells promotes Akt and ERK activation and costimulates IFN-γ production. J Immunol 184: 545-549.
43. Yoo SA, Kwok SK, Kim WU, (2008) Proinflammatory role of vascular endothelial growth factor in the pathogenesis of rheumatoid arthritis: prospects for therapeutic intervention. Mediators Inflamm 2008: 129873-129878.
44. Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF, (2009) Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc Natl Acad Sci USA 106: 21264-21269.
45. Mulligan JK, Rosenzweig SA, Young MR, (2010) Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J Immunother 33: 126-135.
46. Stenzel-Poore M, Vale WW, Rivier C, (1993) Relationship between antigen-induced immune stimulation and activation of the hypothalamic-pituitary-adrenal axis in the rat. Endocrinology 132: 1313-1318.
47. Cupps TR, Gerrard TL, Falkoff RJ, Whalen G, Fauci AS, (1985) Effects of in vitro corticosteroids on B cell activation, proliferation, and differentiation. J Clin Invest 75: 754-761.
48. Lack G, Ochs HD, Gelfand EW, (1996) Humoral immunity in steroid-dependent children with asthma and hypogammaglobulinemia. J Pediatr 129: 898-903.
49. Larsson EL, (1980) Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J Immunol 124: 2828-2833.
50. Bettens F, Kristensen F, Walker C, Schwulera U, Bonnard GD, et al. (1984) Lymphokine regulation of activated (G1) lymphocytes. II. Glucocorticoid and anti-Tac-induced inhibition of human T lymphocyte proliferation. J Immunol 132: 261-265.
51. Gillis S, Crabtree GR, Smith KA, (1979) Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 123: 1624-1631.
52. Ivy SP, Wick JY, Kaufman BM, (2009) An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 6: 569-579.